Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
Posted: 4 September 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations from its bioMUSE natural history study of Multiple…
Approval & first order for Xprecia Prime in India
Posted: 4 September 2023 Universal Biosensors, Inc. (ASX: UBI) is pleased to announce it has received approval from the Indian Central Drugs Standard Control Organisation (CDSCO) for the sale of Xprecia Prime, with the first order received from…
ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections
Posted: 4 September 2023 Clinical-stage pharmaceutical company ENA Respiratory has been awarded an additional $3.8 million contract from the U.S. Department of Defence (DOD) to support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator…
Could a cancer drug hold the key to a HIV cure?
Posted: 4 September 2023 An existing blood cancer drug has shown promise in killing ‘silent’ HIV cells and delaying reinfections – a significant pre-clinical discovery that could lead to a future cure for the disease. Hidden HIV cells,…
More potent treatment for a common cancer mutation provides hope
Posted: 31 August 2023 A tablet taken once a day could be a new treatment used to target one of the key drivers of cancer. Research, published in this month’s New England Journal of Medicine, has shown that divarasib,…
Avecho Conducts $6M Placement to Advance Phase III Clinical Trial
Posted: 29 August 2023 Avecho has received firm commitments to raise $6M via a Placement to support a landmark clinical study testing its proprietary TPM®-enhanced CBD soft-gel capsule for the treatment of insomnia. The Placement was conducted on the same…
New Report Reveals Investors Back Homegrown Future Medical Devices After MRFF Funding
Posted: 29 August 2023 As the second phase of the BioMedTech Horizons (BMTH) program moves to completion, a new report has captured the outcomes of the 38 innovations supported through the program. Launched in May 2017, the BMTH…
National Action Plan Released to Build Australia’s Diagnostic Technology Sector and Improve Health Security
Posted: 29 August 2023 MTPConnect and Pathology Technology Australia (PTA) have today released an Action Plan for establishing an end-to-end sovereign manufacturing capability for diagnostic products in Australia and strengthening supply chain resilience. The Action Plan makes a…
Eureka win for researchers behind new anti-cancer strategy
Posted: 25 August 2023 WEHI researchers Associate Professor Tim Thomas and Professor Anne Voss have won the 2023 UNSW Eureka Prize for Scientific Research for their pioneering work on a novel approach to cancer treatment. The prize recognises their groundbreaking research in…
Firebrick Pharma is just weeks away from finding out if it has cracked a cure for the common cold
Posted: 25 August 2023 How has your winter been? Have you managed to avoid illness like Covid-19, the flu or respiratory viruses associated with the common cold? Over at Firebrick Pharma (ASX:FRE), it’s spent the winter watching its Phase…
Prestigious Eureka Prize win recognises 4DMedical imaging innovation
Posted: 25 August 2023 4DMedical’s unique XV Technology™ has propelled a team of medical researchers to a 2023 Eureka Prize win, announced at a ceremony in Sydney last night. The Australian Museum Eureka Prizes are the country’s most…
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
Posted: 24 August 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the European Patent Office has granted Alterity a new composition…
